The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
|Videos|October 3, 2017
Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma
Author(s)Craig Hofmeister, MD
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.
Advertisement
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.
Patients with multiple myeloma who are fit are usually able to treated with any available agent, says Hofmeister.
The most effective treatment is usually a 3-drug therapy of an immunomodulatory drug, a protostome inhibitor, and dexamethasone, Hofmeister adds.
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
4
Dr Hoffmann on the Significance of Efficacy Data for Sonrotoclax Plus Zanubrutinib in MCL
5